Zuranolone in major depressive disorder: Safety and tolerability results from the phase 3, multicenter, randomized, double-blind, placebo-controlled waterfall study

Authors
Category Primary study
ConferenceNeuropsychopharmacology
Year 2021
This article has no abstract
Epistemonikos ID: 41548f24551867e81e0b4fa62e293efadfc751e5
First added on: Apr 30, 2026